default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

‘GC Wellbeing’s placenta injection has liver regenerative effects’

Lee Han-soo  Published 2019.05.08  17:07  Updated 2019.05.08 17:07

공유
default_news_ad2

GC Wellbeing, a subsidiary of GC, has released the results of a study regarding its placenta injection Laennec’s regenerative effects.

The treatment has won the regulatory approval to improve liver function in patients with chronic liver disease. Human body hydrolysate, its main ingredient, is effective in improving fatigue.

The drug is the only treatment that passed safety and efficacy during the re-evaluation of human body hydrolyzate in 2010.

In the study, the company confirmed the effects of Laennec’s liver regeneration in various fields. As a result, Laennec administration group’s hepatocyte growth factor significantly increased compared to the control group in a liver-resected animal model.

The liver regeneration rate after three days was also 22 percent higher in the treatment group than in the control group, and the company confirmed that the treatment activates cytokine, a substance that helps the liver regeneration.

“The results of this study confirm Laennec's potential to help patients with hepatic resection,” Professor Cho Jae-won of the department of transplantation surgery at Samsung Medical Center. “We plan to continue research on whether Laennec can be used in other related diseases.”

International Journal of Molecular Medicine published the results of the study.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch